^
    Apply
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • ganetespib (ADX-1612) • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • Veppanu (vepdegestrant) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • Oraxol (oral paclitaxel/encequidar) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (NCT01306045)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    02/08/2011
    Primary completion :
    02/12/2014
    Completion :
    12/31/2024
    EGFR • BRAF
    |
    EGFR mutation
    |
    erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206
    Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT01802320)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/20/2019
    Initiation :
    03/01/2013
    Primary completion :
    06/01/2015
    Completion :
    08/05/2015
    KRAS • BRAF • PIK3CA • PTEN
    |
    BRAF mutation • PIK3CA mutation • PTEN mutation • PTEN expression • PIK3CA expression
    |
    MK-2206
    Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer (NCT01277757)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/19/2018
    Initiation :
    03/01/2011
    Primary completion :
    08/01/2014
    Completion :
    08/01/2014
    ER • PIK3CA • PTEN
    |
    ER positive • PIK3CA mutation • EGFR positive • PIK3CA mutation + PTEN mutation
    |
    MK-2206
    AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01253447)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/27/2018
    Initiation :
    10/01/2010
    Primary completion :
    10/01/2013
    Completion :
    04/01/2014
    IL3RA
    |
    MK-2206
    A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010) (NCT01021748)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    08/07/2018
    Initiation :
    11/23/2009
    Primary completion :
    11/26/2012
    Completion :
    07/16/2014
    KRAS
    |
    Koselugo (selumetinib) • MK-2206
    MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT01344031)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/23/2018
    Initiation :
    04/21/2011
    Primary completion :
    07/01/2011
    ER
    |
    fulvestrant • MK-2206 • anastrozole
    Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01369849)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/15/2017
    Initiation :
    09/01/2011
    Primary completion :
    02/01/2014
    Completion :
    02/01/2014
    CD20 • CCND1 • IGH • CD38 • CD5 • ITGA4 • FCER2
    |
    Rituxan (rituximab) • MK-2206 • bendamustine • Novex (rituximab biosimilar)
    PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer (NCT01312753)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/05/2017
    Initiation :
    03/01/2011
    Primary completion :
    01/01/2016
    PIK3CA
    |
    PIK3CA mutation
    |
    MK-2206